Oral spore-based probiotic supplementation was associated with reduced incidence of post-prandial dietary endotoxin, triglycerides, and disease risk biomarkers

To determine if 30-d of oral spore-based probiotic supplementation
could reduce dietary endotoxemia.
Apparently healthy men and women (n = 75) were
screened for post-prandial dietary endotoxemia. Subjects
whose serum endotoxin concentration increased by at
least 5-fold from pre-meal levels at 5-h post-prandial
were considered “responders” and were randomized to
receive either placebo (rice flour) or a commercial sporebased
probiotic supplement [Bacillus indicus (HU36),
Bacillus subtilis (HU58), Bacillus coagulans, and Bacillus
licheniformis, and Bacillus clausii] for 30-d. The dietary
endotoxemia test was repeated at the conclusion of
the supplementation period. Dietary endotoxin (LAL)
and triglycerides (enzymatic) were measured using
World J Gastrointest Pathophysiol 2017 August 15; 8(3): 117-126
ISSN 2150-5330 (online)
Submit a Manuscript: http://www.f6publishing.com
DOI: 10.4291/wjgp.v8.i3.117
Prospective Study
WJGP|www.wjgnet.com 118 August 15, 2017|Volume 8|Issue 3|
McFarlin BK et al . Spore-based probiotics and dietary endotoxemia
an automated chemistry analyzer. Serum disease risk
biomarkers were measured using bead-based multiplex
assays (Luminex and Milliplex) as secondary, exploratory
Data were statistically analyzed using repeated measures
ANOVA and a P < 0.05. We found that spore-based
probiotic supplementation was associated with a 42%
reduction in endotoxin (12.9 ± 3.5 vs 6.1 ± 2.6, P =
0.011) and 24% reduction in triglyceride (212 ± 28 vs
138 ± 12, P = 0.004) in the post-prandial period Placebo
subjects presented with a 36% increase in endotoxin
(10.3 ± 3.4 vs 15.4 ± 4.1, P = 0.011) and 5% decrease
in triglycerides (191 ± 24 vs 186 ± 28, P = 0.004) over
the same post-prandial period. We also found that sporebased
probiotic supplementation was associated with
significant post-prandial reductions in IL-12p70 (24.3 ± 2.2
vs 21.5 ± 1.7, P = 0.017) and IL-1β (1.9 ± 0.2 vs 1.6 ± 0.1,
P = 0.020). Compared to placebo post supplementation,
probiotic subject had less ghrelin (6.8 ± 0.4 vs 8.3 ± 1.1,
P = 0.017) compared to placebo subjects.
The key findings of the present study is that oral sporebased
probiotic supplementation reduced symptoms
indicative of “leaky gut syndrome”.

Leave a Reply

Your email address will not be published. Required fields are marked *